Serine 129 phosphorylation of membrane-associated α-synuclein modulates dopamine transporter function in a G protein-coupled receptor kinase-dependent manner

Molecular Biology of the Cell

Volumn 24, Issue 11, 2013, Pages 1649-1660

  Hara, Susumu ^a   Arawaka, Shigeki ^a   Sato, Hiroyasu ^a   MacHiya, Youhei ^a   Cui, Can ^a   Sasaki, Asuka ^a   Koyama, Shingo ^a   Kato, Takeo ^a  

^a YAMAGATA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; CASEIN KINASE II; DOPAMINE TRANSPORTER; G PROTEIN COUPLED RECEPTOR KINASE; G PROTEIN COUPLED RECEPTOR KINASE 3; G PROTEIN COUPLED RECEPTOR KINASE 5; G PROTEIN COUPLED RECEPTOR KINASE 6; SERINE 129; SERINE DERIVATIVE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTICLE; BIOTINYLATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DOPAMINE UPTAKE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION;

ALPHA-SYNUCLEIN; BIOLOGICAL TRANSPORT; CASEIN KINASE II; CELL LINE; CELL MEMBRANE; DOPAMINE; G-PROTEIN-COUPLED RECEPTOR KINASE 3; G-PROTEIN-COUPLED RECEPTOR KINASE 5; G-PROTEIN-COUPLED RECEPTOR KINASES; GENE EXPRESSION REGULATION; HEK293 CELLS; HUMANS; NEURONS; PHOSPHORYLATION; RNA, SMALL INTERFERING; SERINE; SIGNAL TRANSDUCTION;

EID: 84878682977     PISSN: 10591524     EISSN: 19394586     Source Type: Journal    
DOI: 10.1091/mbc.E12-12-0903     Document Type: Article

References (54)

1. Anderson JP et al. (2006). Phosphorylation of Ser-129 is the dominant pathological modification ofα-synuclein in familial and sporadic Lewy body disease. J Biol Chem 281, 29739-29752. (Pubitemid 44536983)
2. Arawaka S et al. (2002). The levels of mature glycosylated nicastrin are regulated and correlate with γ-secretase processing of amyloid β-precursor protein. J Neurochem 83, 1065-1071. (Pubitemid 35397116)
3. Boekhoff I, Inglese J, Schleicher S, Koch WJ, Lefkowitz RJ, Breer H (1994). Olfactory desensitization requires membrane targeting of receptor kinase mediated by beta gamma-subunits of heterotrimeric G proteins. J Biol Chem 269, 37-40. (Pubitemid 24026616)
4. Chadchankar H, Ihalainen J, Tanila H, Yavich L (2011). Decreased reuptake of dopamine in the dorsal striatum in the absence of alpha-synuclein. Brain Res 1382, 37-44.
5. Chandra S et al. (2004). Double-knockout mice for α- and β-synucleins: effect on synaptic functions. Proc Natl Acad Sci USA 101, 14966-14971. (Pubitemid 39410782)
6. Chen L, Feany MB (2005). α-Synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. Nat Neurosci 8, 657-663. (Pubitemid 40594208)
7. Chen L, Periquet M, Wang X, Negro A, McLean PJ, Hyman BT, Feany MB (2009). Tyrosine and serine phosphorylation of α-synuclein have opposing effects on neurotoxicity and soluble oligomer formation. J Clin Invest 119, 3257-3265.
8. Conway KA, Rochet JC, Bieganski RM, Lansbury PT Jr (2001). Kinetic stabilization of the α-synuclein protofibril by a dopamine-α- synuclein adduct. Science 294, 1346-1349. (Pubitemid 33063102)
9. Dauer W et al. (2002). Resistance of α-synuclein null mice to the parkinsonian neurotoxin MPTP. Proc Natl Acad Sci USA 99, 14524-14529. (Pubitemid 35257704)
10. Davidson WS, Jonas A, Clayton DF, George JM (1998). Stabilization of α-synuclein secondary structure upon binding to synthetic membranes. J Biol Chem 273, 9443-9449. (Pubitemid 28183026)
11. DebBurman SK, Ptasienski J, Boetticher E, Lomasney JW, Benovic JL, Hosey MM (1995). Lipid-mediated regulation of G protein-coupled receptor kinases 2 and 3. J Biol Chem 270, 5742-5747.
12. Dettmer U, Newman AJ, Luth ES, Bartels T, Selkoe D (2013). In vivo cross-linking reveals principally oligomeric forms of α-synuclein and β-synuclein in neurons and non-neural cells. J Biol Chem 288, 6371-6385.
13. Eriksen JL, Dawson TM, Dickson DW, Petrucelli L (2003). Caught in the act: α-synuclein is the culprit in Parkinson's disease. Neuron 40, 453-456. (Pubitemid 37494695)
14. Fountaine TM, Wade-Martins R (2007). RNA interference-mediated knockdown of α-synuclein protects human dopaminergic neuroblastoma cells from MPP(+) toxicity and reduces dopamine transport. J Neurosci Res 85, 351-363. (Pubitemid 46219303)
15. Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS, Shen J, Takio K, Iwatsubo T (2002). α-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 4, 160-164.
16. Ihara M et al. (2007). Sept4, a component of presynaptic scaffold and Lewy bodies, is required for the suppression of α-synuclein neurotoxicity. Neuron 53, 519-533. (Pubitemid 46216751)
17. Inglis KJ et al. (2009). Polo-like kinase 2 (PLK2) phosphorylates α-synuclein at serine 129 in central nervous system. J Biol Chem 284, 2598-2602.
18. Ito K, Haga T, Lameh J, Sadee W (1999). Sequestration of dopamine D2 receptors depends on coexpression of G-protein-coupled receptor kinases 2 or 5. Eur J Biochem 260, 112-119. (Pubitemid 29095701)
19. Jiang H, Jiang Q, Feng J (2004). Parkin increases dopamine uptake by enhancing the cell surface expression of dopamine transporter. J Biol Chem 279, 54380-54386. (Pubitemid 40053177)
20. Jiang X, Benovic JL, Wedegaertner PB (2007). Plasma membrane and nuclear localization of G protein-coupled receptor kinase 6A. Mol Biol Cell 18, 2960-2969. (Pubitemid 47235303)
21. Karube H et al. (2008). N-terminal region of α-synuclein is essential for the fatty acid-induced oligomerization of the molecules. FEBS Lett 582, 3693-3700.
22. Kim KM, Valenzano KJ, Robinson SR, Yao WD, Barak LS, Caron MG (2001). Differential regulation of the dopamine D2 and D3 receptors by G protein-coupled receptor kinases and beta-arrestins. J Biol Chem 276, 37409-37414.
23. Kruger R et al. (1998). Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease. Nat Genet 18, 106-108.
24. Lee BR, Kamitani T (2011). Improved immunodetection of endogenous α-synuclein. PLoS One 6, e23939.
25. Lee FJ, Liu F, Pristupa ZB, Niznik HB (2001). Direct binding and functional coupling of α-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. FASEB J 15, 916-926. (Pubitemid 32290778)
26. Lee FJ, Pei L, Moszczynska A, Vukusic B, Fletcher PJ, Liu F (2007). Dopamine transporter cell surface localization facilitated by a direct interaction with the dopamine D2 receptor. EMBO J 26, 2127-2136. (Pubitemid 46625791)
27. Lee VM, Trojanowski JQ (2006). Mechanisms of Parkinson's disease linked to pathological α-synuclein: new targets for drug discovery. Neuron 52, 33-38. (Pubitemid 44479831)
28. Lundblad M, Decressac M, Mattsson B, Bjorklund A (2012). Impaired neurotransmission caused by overexpression of α-synuclein in nigral dopamine neurons. Proc Natl Acad Sci USA 109, 3213-3219.
29. Machiya Y, Hara S, Arawaka S, Fukushima S, Sato H, Sakamoto M, Koyama S, Kato T (2010). Phosphorylated α-synuclein at Ser-129 is targeted to the proteasome pathway in a ubiquitin-independent manner. J Biol Chem 285, 40732-40744.
30. Martinez-Vicente M et al. (2008). Dopamine-modified α-synuclein blocks chaperone-mediated autophagy. J Clin Invest 118, 777-788.
31. Mbefo MK et al. (2010). Phosphorylation of synucleins by members of the Polo-like kinase family. J Biol Chem 285, 2807-2822.
32. McLean PJ, Kawamata H, Ribich S, Hyman BT (2000). Membrane association and protein conformation of α-synuclein in intact neurons. Effect of Parkinson's disease-linked mutations. J Biol Chem 275, 8812-8816. (Pubitemid 30180236)
33. Mosharov EV et al. (2009). Interplay between cytosolic dopamine, calcium, and α-synuclein causes selective death of substantia nigra neurons. Neuron 62, 218-229.
34. Oaks AW, Sidhu A (2011). Synuclein modulation of monoamine transporters. FEBS Lett 585, 1001-1006.
35. Okochi M, Walter J, Koyama A, Nakajo S, Baba M, Iwatsubo T, Meijer L, Kahle PJ, Haass C (2000). Constitutive phosphorylation of the Parkinson's disease associated α-synuclein. J Biol Chem 275, 390-397. (Pubitemid 30038997)
36. Perrin RJ, Woods WS, Clayton DF, George JM (2000). Interaction of human α-synuclein and Parkinson's disease variants with phospholipids. Structural analysis using site-directed mutagenesis. J Biol Chem 275, 34393-34398.
37. Polymeropoulos MH et al. (1997). Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 276, 2045-2047. (Pubitemid 27443610)
38. Premont RT, Inglese J, Lefkowitz RJ (1995). Protein kinases that phosphorylate activated G protein-coupled receptors. FASEB J 9, 175-182.
39. Pronin AN, Morris AJ, Surguchov A, Benovic JL (2000). Synucleins are a novel class of substrates for G protein-coupled receptor kinases. J Biol Chem 275, 26515-26522.
40. Reiter E, Lefkowitz RJ (2006). GRKs and beta-arrestins: roles in receptor silencing, trafficking and signaling. Trends Endocrinol Metab 17, 159-165.
41. Richfield EK, Thiruchelvam MJ, Cory-Slechta DA, Wuertzer C, Gainetdinov RR, Caron MG, Di Monte DA, Federoff HJ (2002). Behavioral and neurochemical effects of wild-type and mutated human α-synuclein in transgenic mice. Exp Neurol 175, 35-48. (Pubitemid 34507908)
42. Sakamoto M et al. (2009). Contribution of endogenous G-protein-coupled receptor kinases to Ser129 phosphorylation of α-synuclein in HEK293 cells. Biochem Biophys Res Commun 384, 378-382.
43. Sato H, Arawaka S, Hara S, Fukushima S, Koga K, Koyama S, Kato T (2011). Authentically phosphorylated α-synuclein at Ser129 accelerates neurodegeneration in a rat model of familial Parkinson's disease. J Neurosci 31, 16884-16894.
44. Sharon R, Bar-Joseph I, Frosch MP, Walsh DM, Hamilton JA, Selkoe DJ (2003). The formation of highly soluble oligomers of α-synuclein is regulated by fatty acids and enhanced in Parkinson's disease. Neuron 37, 583-595. (Pubitemid 36262981)
45. Singleton AB et al. (2003). α-Synuclein locus triplication causes Parkinson's disease. Science 302, 841. (Pubitemid 37339619)
46. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M (1997). α-Synuclein in Lewy bodies. Nature 388, 839-840.
47. Stoffel RH, Inglese J, Macrae AD, Lefkowitz RJ, Premont RT (1998). Palmitoylation increases the kinase activity of the G protein-coupled receptor kinase, GRK6. Biochemistry 37, 16053-16059. (Pubitemid 28536242)
48. Stoffel RH, Randall RR, Premont RT, Lefkowitz RJ, Inglese J (1994). Palmitoylation of G protein-coupled receptor kinase, GRK6. Lipid modification diversity in the GRK family. J Biol Chem 269, 27791-27794.
49. Thiyagarajan MM, Stracquatanio RP, Pronin AN, Evanko DS, Benovic JL, Wedegaertner PB (2004). A predicted amphipathic helix mediates plasma membrane localization of GRK5. J Biol Chem 279, 17989-17995. (Pubitemid 38560568)
50. Venda LL, Cragg SJ, Buchman VL, Wade-Martins R (2010). α-Synuclein and dopamine at the crossroads of Parkinson's disease. Trends Neurosci 33, 559-568.
51. Volles MJ, Lee SJ, Rochet JC, Shtilerman MD, Ding TT, Kessler JC, Lansbury PT Jr (2001). Vesicle permeabilization by protofibrillar α-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry 40, 7812-7819. (Pubitemid 32622972)
52. Xu J, Kao SY, Lee FJ, Song W, Jin LW, Yankner BA (2002). Dopamine-dependent neurotoxicity of α-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nat Med 8, 600-606. (Pubitemid 34633438)
53. Yamakado H, Moriwaki Y, Yamasaki N, Miyakawa T, Kurisu J, Uemura K, Inoue H, Takahashi M, Takahashi R (2012). α-Synuclein BAC transgenic mice as a model for Parkinson's disease manifested decreased anxiety-like behavior and hyperlocomotion. Neurosci Res 73, 173-177.
54. Zarranz JJ et al. (2004). The new mutation, E46K, of α-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 55, 164-173. (Pubitemid 38166992)